Galamb O, Kalmár A, Barták BK, Patai &V, Leiszter K, Péterfia B, Wichmann B, Valcz G, Veres G, Tulassay Z, Molnár B. Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma. World J Gastroenterol 2016; 22(47): 10325-10340 [PMID: 28058013 DOI: 10.3748/wjg.v22.i47.10325]
Corresponding Author of This Article
Orsolya Galamb, PhD, 2nd Department of Internal Medicine, Semmelweis University, Szentkirályi str 46, H-1088 Budapest, Hungary. orsg1@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Orsolya Galamb, Barnabás Wichmann, Gábor Valcz, Zsolt Tulassay, Béla Molnár, Molecular Medicine Research Group, Hungarian Academy of Sciences, H-1088 Budapest, Hungary
Orsolya Galamb, Alexandra Kalmár, Barbara Kinga Barták, Árpád V Patai, Katalin Leiszter, Bálint Péterfia, 2nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Hungary
Gábor Veres, 1st Department of Paediatrics, Semmelweis University, H-1083 Budapest, Hungary
ORCID number: $[AuthorORCIDs]
Author contributions: Galamb O, Kalmár A, Péterfia B and Molnár B designed the study; Patai ÁV, Veres G and Molnár B collected the samples; Galamb O, Patai ÁV, Leiszter K, Valcz G and Veres G contributed to the collection of clinical data and histological analysis of the samples; Galamb O, Kalmár A, Barták BK and Patai ÁV performed the experiments; Galamb O, Kalmár A, Wichmann B and Valcz G analyzed the experimental data; Tulassay Z and Molnár B contributed to the design and critical review of the manuscript, obtained fundings; all authors were involved in writing the paper, made a critical revision of the manuscript for important intellectual content and had final approval of the submitted and published versions.
Supported bythe National Research, Development and Innovation Office, No. KMR-12-1-2012-0216; and the Hungarian Scientific Research Fund, No. OTKA-K111743.
Institutional review board statement: All routine colonic biopsy samples from the patients were taken after informed consent and ethical permission was obtained for participation in the study.
Conflict-of-interest statement: The authors declare that no conflict of interest exists.
Data sharing statement: Additional data are available in a supplementary file.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Orsolya Galamb, PhD, 2nd Department of Internal Medicine, Semmelweis University, Szentkirályi str 46, H-1088 Budapest, Hungary. orsg1@yahoo.com
Telephone: +36-1-2660926 Fax: +36-1-2660816
Received: June 22, 2016 Peer-review started: June 24, 2016 First decision: August 22, 2016 Revised: September 20, 2016 Accepted: November 13, 2016 Article in press: November 13, 2016 Published online: December 21, 2016 Processing time: 180 Days and 3 Hours
Abstract
AIM
To analyze colorectal carcinogenesis and age-related DNA methylation alterations of gene sequences associated with epigenetic clock CpG sites.
METHODS
In silico DNA methylation analysis of 353 epigenetic clock CpG sites published by Steve Horvath was performed using methylation array data for a set of 123 colonic tissue samples [64 colorectal cancer (CRC), 42 adenoma, 17 normal; GEO accession number: GSE48684]. Among the differentially methylated age-related genes, secreted frizzled related protein 1 (SFRP1) promoter methylation was further investigated in colonic tissue from 8 healthy adults, 19 normal children, 20 adenoma and 8 CRC patients using bisulfite-specific PCR followed by methylation-specific high resolution melting (MS-HRM) analysis. mRNA expression of age-related “epigenetic clock” genes was studied using Affymetrix HGU133 Plus2.0 whole transcriptome data of 153 colonic biopsy samples (49 healthy adult, 49 adenoma, 49 CRC, 6 healthy children) (GEO accession numbers: GSE37364, GSE10714, GSE4183, GSE37267). Whole promoter methylation analysis of genes showing inverse DNA methylation-gene expression data was performed on 30 colonic samples using methyl capture sequencing.
RESULTS
Fifty-seven age-related CpG sites including hypermethylated PPP1R16B, SFRP1, SYNE1 and hypomethylated MGP, PIPOX were differentially methylated between CRC and normal tissues (P < 0.05, Δβ≥ 10%). In the adenoma vs normal comparison, 70 CpG sites differed significantly, including hypermethylated DKK3, SDC2, SFRP1, SYNE1 and hypomethylated CEMIP, SPATA18 (P < 0.05, Δβ≥ 10%). In MS-HRM analysis, the SFRP1 promoter region was significantly hypermethylated in CRC (55.0% ± 8.4 %) and adenoma tissue samples (49.9% ± 18.1%) compared to normal adult (5.2% ± 2.7%) and young (2.2% ± 0.7%) colonic tissue (P < 0.0001). DNA methylation of SFRP1 promoter was slightly, but significantly increased in healthy adults compared to normal young samples (P < 0.02). This correlated with significantly increased SFRP1 mRNA levels in children compared to normal adult samples (P < 0.05). In CRC tissue the mRNA expression of 117 age-related genes were changed, while in adenoma samples 102 genes showed differential expression compared with normal colonic tissue (P < 0.05, logFC > 0.5). The change of expression for several genes including SYNE1, CLEC3B, LTBP3 and SFRP1, followed the same pattern in aging and carcinogenesis, though not for all genes (e.g., MGP).
CONCLUSION
Several age-related DNA methylation alterations can be observed during CRC development and progression affecting the mRNA expression of certain CRC- and adenoma-related key control genes.
Core tip: Several age-related DNA methylation alterations could be observed during colorectal cancer (CRC) formation and progression affecting the mRNA expression of certain CRC- and adenoma-related key control genes such as hypermethylated secreted frizzled related protein 1 (SFRP1), spectrin repeat containing nuclear envelope protein 1 and hypomethylated cell migration-inducing protein. For the first time significantly lower SFRP1 methylation levels were demonstrated in colonic tissue from children (under 18 years) compared to healthy adults. The main CRC-associated signal transduction pathways, such as WNT signaling and PI3K/Akt pathways are also influenced during aging.
Citation: Galamb O, Kalmár A, Barták BK, Patai &V, Leiszter K, Péterfia B, Wichmann B, Valcz G, Veres G, Tulassay Z, Molnár B. Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma. World J Gastroenterol 2016; 22(47): 10325-10340
DNA methylation alterations in connection with aging include epigenetic drift and epigenetic clock phenomena. Epigenetic drift is defined as the global DNA methylation changes caused by random and environmental individual-specific factors, while the epigenetic clock is defined as a group of progressive age-related epigenetic alterations at specific genomic sites which are common across individuals and occassionally across various tissue types[1,2]. The epigenetic clock concept is an approach to biological age prediction of different tissues based on the DNA methylation status of 353 CpG sites measured using the Illumina Beadchip450K methylation array platform[2].
Although age-related (A type) and cancer-related (C type) DNA methylation are often distinguished, the main age-related disease is cancer and the age of patients is one of the risk factor for carcinogenesis[3]. In human development, following a transient increase in average DNA methylation in early childhood (during the first year of life)[4,5], global hypomethylation is characteristic during aging[6,7]. Similarly global hypomethylation is observed in various types of cancers including colorectal cancer (CRC)[8]. With aging, besides global hypomethylation, local hypermethylation can occur on promoters of certain genes, including tumor suppressor gene promoters in various types of cancers, and many tumor suppressor genes were reported among the age-dependently hypermethylated genes[6]. Among others, promoter hypermethylation of APC[7,9-12], CDKN2A[7,9], ESR1[7,13,14], GATA5[15,16], HPP1[7,15,17], SFRP1[7,12,15,18-23] and SFRP2[7,18-21] genes was reported for colonic tissues during both aging and colorectal carcinogenesis. Although DNA methylation data from adult colonic tissue samples has been expansively published, data for children/young patients are limited.
In this study, we analyzed DNA methylation and/or gene expression changes of genes covered by the 353 epigenetic clock CpG sites[2] for patients of different ages as well as stages in the progression through to CRC in order to study the possible relationship between age-related and cancer-associated epigenetic alterations. Gene expression analysis was performed using colonic tissue samples from healthy children, healthy adults, and patients with adenomas and CRC. Among the differentially methylated/expressed age-related genes, secreted frizzled related protein 1 (SFRP1) promoter methylation was further analyzed in healthy, premalignant and cancerous colonic tissue samples, and to our knowledge this is the first study to also include colonic biopsy specimens from children.
MATERIALS AND METHODS
In silico DNA methylation analysis
The DNA methylation status of 353 age-related CpG sites[2] was analyzed in silico using methylation array data from the Illumina BeadChip450K. Analysis was performed on 123 CRC, adenoma and normal tissue samples available in the NCBI Gene Expression Database database (GEO accession number: GSE48684[24]). Differences between average methylation values of the compared diagnostic groups (Δβ-values) and P values were determined for each CpG site (cg IDs). For statistical evaluation, normal distribution was checked using Kolmogorov-Smirnov test. Hence normal distribution was observed in any cases, Student’s t-test with Benjamini and Hochberg correction was applied for paired group comparisons. Significance criteries were P < 0.05 in all cases.
In silico gene expression analysis
The expression of age-related “epigenetic clock” genes was analyzed using whole transcriptome data from Affymetrix HGU133 Plus2.0. Data was obtained from 153 colonic biopsy samples (49 healthy, 49 adenoma, 49 CRC and 6 healthy children) previously hybridized by our research group (GEO serial accession numbers: GSE37364[25], GSE10714[26], GSE4183[27], GSE37267[28]). Gene expression levels were compared using unpaired Student’s t-test with Benjamini and Hochberg correction (P value of < 0.05 was considered as significant). For gene expression analysis, normal distribution was found using Kolmogorov-Smirnov test, therefore Student’s t-test (in case of differentiation of two groups with equal variances) or Welch-test (in case of differentiation of two groups with unequal variances) and ANOVA (when more than two groups were compared) were applied. For paired comparisons Benjamini and Hochberg correction was applied. In case of ANOVA, Tukey HSD post-test was used in order to find out which group refers to the differentiation if any. Significance criteries were P < 0.05 in any cases. For the logFC calculation, the differences between the averages of groups were considered (abs logFC ≥ 0.5 criteria).
Methyl capture sequencing - in silico data analysis
Whole methylome data from 6 normal adjacent tissue (NAT), 15 adenoma and 9 CRC tissue samples were determined in a previous study using methyl capture sequencing[12]. Using this dataset, the whole promoter methylation status of genes showing an inverse relation between gene expression and DNA methylation was evaluated. Differentially methylated genes were determined as described earlier[12]. For statistical evaluation normal distribution was determined and the applied tests were chosen according to the above-mentioned criteria. Differences with P < 0.05 were considered as significant. Methylation alterations between diagnostic groups were characterized by Δβ-values (the differences of the average β-values of sample groups).
Clinical samples
All patients provided informed consent. Colorectal biopsy samples were obtained during routine endoscopic intervention at the 2nd Department of Internal Medicine and 1st Department of Paediatrics, Semmelweis University, Budapest, Hungary. In total 55 colonic tissue samples (from 19 healthy children (under age of 18 years), 8 healthy adults, 20 patients with adenomas and 8 CRC samples) were tested in SFRP1 methylation-specific high resolution melting (MS-HRM) study (Table 1). Biopsy samples from all adults and 5 of children were stored in RNALater Stabilization Solution (Ambion, ThermoFisher Scientific) at -80 °C until use. Biopsy samples from the same site were immediately fixed in buffered formalin for histological evaluation. For 14 children, only FFPE blocks were available. Histological diagnoses were established by experienced pathologists. Altogether 27 tissue samples (19 from children and 8 from adults) with normal histology (so called healthy normal colonic tissue samples) were involved in SFRP1 MS-HRM study. Children and adults in the study had been referred to the outpatient clinic with rectal bleeding, constipation or chronic abdominal pain. Ileocolonoscopy was part of their diagnostic procedure (exclude organic disease) and the biopsy specimens showed normal macroscopic appearance and histology[28]. The study was conducted according to the Helsinki declaration and approved by the local ethics committee and government authorities (Regional and Institutional Committee of Science and Research Ethics (TUKEB) Nr.: 69/2008, 202/2009 and 23970/2011 Semmelweis University, Budapest, Hungary).
Table 1 Clinical data of samples involved in the high resolution melting study.
Sample ID
Age
Gender
Localization
Histology
TNM
Grade
Dukes’ stage (MAC)
Dysplasia
Adenoma size
Sample type
Ch1
4
M
Colon
Normal
FFPE
Ch2
7
F
Cecum
Normal
FFPE
Ch3
11
M
Colon
Normal
FFPE
Ch4
14
M
Transverse
Normal
FFPE
Ch5
5
F
Sigmoid
Normal
FFPE
Ch6
7
F
Descendent
Normal
FFPE
Ch7
1
M
Descendent
Normal
FFPE
Ch8
1
M
Sigmoid
Normal
FFPE
Ch9
10
M
Cecum
Normal
FFPE
Ch10
3
M
Sigmoid
Normal
FFPE
Ch11
17
F
Cecum
Normal
FFPE
Ch12
17
F
Sigmoid
Normal
FFPE
Ch13
16
F
Sigmoid
Normal
FFPE
Ch14
16
F
Cecum
Normal
FFPE
Ch15
1
M
Left colon
Normal
FF
Ch16
3
F
Sigmoid
Normal
FF
Ch17
6
M
Sigmoid
Normal
FF
Ch18
9
M
Sigmoid
Normal
FF
Ch19
17
M
Colon
Normal
FF
N1
44
F
Sigmoid
Normal
FF
N2
31
F
Sigmoid
Normal
FF
N3
59
F
Sigmoid
Normal
FF
N4
54
M
Colon
Normal
FF
N5
68
F
Sigmoid
Normal
FF
N6
71
F
Sigmoid
Normal
FF
N7
69
F
Sigmoid
Normal
FF
N8
57
F
Sigmoid
Normal
FF
AD1
78
M
Asc, sigmoid, rectum
Tubulovillous adenoma
Low-grade
30 mm, 3 mm, 15 mm
FF
AD2
60
M
Sigmoid
Tubular adenoma
Low-grade
6 mm
FF
AD3
88
M
Asc, transv, sigmoid
Tubular adenoma
Low-grade
4 mm, 3 mm, 7-8 mm
FF
AD4
72
F
Rectum
Tubular adenoma
Low-grade
10 mm
FF
AD5
45
F
Descendent
Tubular adenoma
High-grade
5-6 mm
FF
AD6
68
F
Rectum
Tubular adenoma
Low-grade
5 mm
FF
AD7
63
F
Sigmoid
Tubular adenoma
Low-grade
8 mm
FF
AD8
65
F
Asc, transv, rectum
Tubular adenoma
Low-grade
2-3 mm, 2-3 mm, 2-3 mm
FF
AD9
60
F
Sigmoid
Tubular adenoma
Low-grade
5 mm, 4 mm
FF
AD10
77
F
Rectosigmoid
Tubular adenoma
Low-grade
5 mm
FF
AD11
55
F
Asc colon
Tubular adenoma
Low-grade
10 mm
FF
AD12
76
M
Cecum, sigmoid
Tubular adenoma
Low-grade
5 mm, 8-10 mm
FF
AD13
62
F
Sigmoid
Tubular adenoma
High-grade
30 mm
FF
AD14
83
M
Asc colon
Tubulovillous adenoma
High-grade
50-60 mm
FF
AD15
73
M
Cecum, asc, desc
Tubular adenoma
Low-grade
12 mm, 10 mm, 6-8 mm
FF
AD16
64
M
Transv, sigmoid, rectum
Tubular adenoma
Low-grade
5 mm, 25 mm, 15 mm
FF
AD17
63
M
Asc, transv, rectum
Tubular adenoma
Low-grade
2-3 mm, 5 mm, 5-6 mm, 15 mm
FF
AD18
63
F
Sigmoid
Tubulovillous adenoma
Low-grade
25 mm
FF
AD19
63
M
Rectum
Tubulovillous and tubular adenoma
Low-grade
25 mm, 30 mm
FF
AD20
87
M
Sigmoid, rectum
Tubulovillous adenoma
Low-grade
20 mm, 15 mm
FF
AD21
63
F
Sigmoid
Tubulovillous adenoma
Low-grade
25 mm
FF
CRC1
67
F
Sigmoid
Adenocarcinoma
Unknown
Unknown
Unknown
FF
CRC2
76
F
Hepatic flexure
Adenocarcinoma
T2N0M0
2
B1
FF
CRC3
73
F
Sigmoid
Adenocarcinoma
T3N2M1
2
D
FF
CRC4
65
M
Sigmoid
Adenocarcinoma
T2N0M0
1
B1
FF
CRC5
85
F
Cecum
Adenocarcinoma
T2N0M0
2
B1
FF
CRC6
60
M
Hepatic flexure
Adenocarcinoma
unknown
D
FF
CRC7
68
M
Sigmoid, rectum
Adenocarcinoma
T3N0M0
1
B2
FF
CRC8
87
F
Sigmoid
Adenocarcinoma
T3N0M0
2
B2
FF
DNA isolation
Tissue samples were homogenized in 2% sodium dodecyl sulphate, and digested with 4 mg/mL proteinase K for 16 h at 56 °C. Genomic DNA was isolated using the High Pure PCR Template Preparation Kit (Roche Applied Science) according to the manufacturer’s instructions[18]. DNA was eluted in 2 × 100 μL RNase- and DNase-free water and stored at -20 °C. The quantity of the isolated DNA samples was measured by Qubit fluorometer using the Qubit dsDNA HS Assay (Invitrogen, ThermoFisher Scientific).
Bisulfite-specific PCR and MS-HRM experiments for SFRP1 promoter methylation analysis
Bisulfite conversion was performed using the EZ DNA Methylation Direct™ Kit (Zymo Research, Irvine, CA, United States) according to the manufacturer’s instructions. For fresh frozen samples, 500 ng isolated DNA was converted, while for FFPE samples the total recovered DNA after deparaffinization and digestion was bisulfite converted. Bisulfite-specific PCR (BS-PCR) reactions were performed in 15 μL volume using LightCycler 480 Probes Master (Roche Applied Science), LightCycler® 480 ResoLight Dye (Roche), SFRP1 primers at 0.2 μmol/L final concentrations and bisulfite converted DNA (bcDNA) samples (approx, 5 ng bcDNA/well). The sequences of the applied SFRP1 BS-PCR primers were previously described[19]. Real-time PCR amplification was carried out on LightCycler 480 System with the following thermocycling conditions: 95 °C for 10 min, then 95 °C for 30 s, 62 °C with 0.4 °C decreasement/cycle for 30 s, 72 °C for 30 s for 10 touchdown cycles, followed by the amplification at 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s in 50 cycles. For HRM calibration, unmethylated and methylated bisulfite converted control DNA (EpiTect PCR Control DNA Set, Qiagen) were used in different ratios (0%, 10%, 25%, 50%, 75% and 100% methylated controls). HRM analyis was performed according to the following thermal conditions: after denaturation at 95 °C for 1 min, and cooling at 40 °C for 1 min, the reactions were continuously warmed up to 95 °C with a 25 acquisition/°C rate. Raw HRM data were exported and the HRM peak heights of the negative derivative of fluorescence over temperature curves (-(d/dT) Fluorescence) of the biological samples were retrieved at the melting temperatures of the methylated and unmethylated standards. The methylation percent was calculated by the ratio of values at the methylated and unmethylated melting temperatures. For statistical evaluation normal distribution was determined and the applied tests were chosen according to the above-mentioned criteria.
SFRP1 immunohistochemistry
Parallel with our epigenetic examinations, 4 nm thick FFPE samples from healthy children (n = 6) and healthy adults (n = 7) were examined. SFRP1 immunohistochemistry was performed on colonic tissue samples of healthy adults (n = 7; mean age at histology examination: 48 ± 17 years; 5 f/2 m) and of children (mean age: 12 ± 6 years); 3 f/3 m). Histology was diagnosed by an expert pathologist on routinely stained HE sections. Following deparaffinization and rehydration, microwave based antigen retrieval was performed in TRIS EDTA buffer (pH 9.0) (900 W/10 min, then 340 W/40 min). Samples were immunostained with SFRP1 polyclonal antibody (ab4193, Abcam, Cambridge, United Kingdom, 1:80 dilution) with diaminobenzidine - hydrogen peroxidase - chromogen-substrate system (cat#30014.K, HISTOLS-DAB, Histopathology Ltd., Hungary) and were digitalized by Pannoramic 250 Flash II scanner (with Zeiss Plan-Apochromat 20 × objective; 3DHISTECH Ltd, Hungary). Digital slides were semi-quantitatively analyzed with Pannoramic Viewer (ver.:1.15.3; 3DHISTECH) based on Q-score method (scored by multiplying the percentage of positive cells (P) by the intensity (I: +3, +2, +1, 0). Formula: Q = P × I; Maximum = 300). Epithelial and stromal compartments were examined separately, then these scores were summarized (Σ) (Σ Q-score maximum: 600) in order to have comparable results with our whole biopsy methylation analyses.
Statistical analysis
The applied statistical methods are outlined above after the descriptions of molecular and in silico analyses. The statistical review of the study was performed by a biomedical statistician.
RESULTS
Gene ontology of 353 CpG sites of the "epigenetic clock"
The “epigenetic clock” signature includes 353 CpG sites[2] including different genes, gene promoters and other genomic regions such as enhancers, insulators, Polycomb-repressed regions. From the above 353 CpG sites, DNA methylation levels of 193 were positively and of 160 were negatively correlated with age[2]. First we updated the annotation of the CpG sites and assigned official gene symbols according to the newest version of NCBI Gene Database. Approximately 80% of the genes belonging to 353 CpG sites could be classified into functional groups including highly represented transcriptional regulation, translation (15.93%), metabolism (12.36%), development and ontogenesis (8.24%) and transport (8.24%). Approximately 20% of the genes had unknown function. According to the Encode ChromHMM results of nine human cell lines, the majority of the 353 CpG sites (76.2 %) were located in the promoter regions of genes. Also, 57.2% of them were categorized as active promoters (declared if it was found “active promoter” in at least one of the nine analyzed cell lines), while 19% were found to be “weak promoter” (“weak promoter” in at least one of the nine analyzed cell lines). One fourth (23.8%) of the CpG sites was located in non-promoter regions such as enhancers, insulators, transcribed and repressed regions (Supplementary Table 1).
In silico DNA methylation analysis
Analysis of the Illumnina Beadchip450K methylation array data set of Luo et al[24] showed 137 (38.8%) of the epigenetic clock CpG sites were found to be significantly differentially methylated between CRC and normal tissue samples (P < 0.05). Approximately two third of these CpG sites had similar methylation changes in CRC samples as during aging, while one third of these CpG sites showed opposite alterations in CRC tissue as during aging (Supplementary Table 1). Among these, 57 CpG sites showed at least a 10% methylation difference: from the 57 CpG sites 45 were hypermethylated (including ADHFE1/cg08090772, MCAM/cg21096399, DKK3/cg13216057, SFRP1/cg02388150, SYNE1/cg26620959), while 12 CpG sites showed hypomethylation (such as MGP/cg00431549, PIPOX/cg06144905, STRA6/cg00075967, ERG/cg17274064) in CRCs (P < 0.05, Δβ≥ 10%) (Table 2, Supplementary Table 1). In the adenoma vs normal comparison, DNA methylation of 165 CpG sites (46.7%) were significantly altered from which 70 CpG sites showed a ≥ 10% methylation difference: 36 CpG sites were hypermethylated (e.g., SDC2/cg25070637, SFRP1/cg02388150, SYNE1/cg26620959) and 34 showed decreased methylation levels (including CEMIP/cg20828084, SPATA18/cg03103192, STRA6/cg00075967) in adenoma samples (P < 0.05, Δβ≥ 10%) (Table 3). In CRC samples 33 CpG sites were found to be hypermethylated (such as KRT20/cg00091693, STRA6/cg00075967, UROS/cg19346193) and only one (LTBP3/cg08965235) was hypomethylated compared to adenomas (P < 0.05, Δβ≥ 10%) (Table 4). A heatmap for the differentially methylated epigenetic clock CpG sites (P < 0.05, Δβ≥ 10%), with hierarchical cluster analysis results of normal, adenoma and CRC samples is shown in Figure 1.
Figure 1 DNA methylation heatmap of normal, adenoma and colorectal carcinoma samples according to the methylation status of age-related CpG sites.
From the 353 epigenetic clock CpG sites (cg IDs)[2] significantly differentially methylated in CRC vs normal, adenoma vs normal and CRC vs adenoma comparisons were selected and colonic tissue samples (GSE48684[24]) were classified according to their methylation levels. The analyzed samples are illustrated on X axis, significantly altered CpG sites (cg IDs) are represented on Y axis. DNA methylation intensities (β values) are visualized, red shows hypermethylation, while hypomethylation was marked with green color. CRC: Colorectal carcinoma (light green); Ad: Adenoma (dark blue); N: Normal (light blue).
Table 2 Significant DNA methylation alterations of age-related CpG sites in CRC samples compared to normal tissue.
cgID
Gene symbol
P value
Δβ (CRC - N)
cg06462291
NT5DC3
3.81 × 10-6
-0.27
cg06144905
PIPOX
1.81 × 10-7
-0.22
cg10345936
SLC36A2
2.49 × 10-5
-0.18
cg13828047
MPI
1.78 × 10-5
-0.17
cg11314684
AKT3
4.55 × 10-5
-0.16
cg00431549
MGP
0.020
-0.12
cg14409958
ENPP2
0.021
-0.11
cg00091693
KRT20
0.010
-0.11
cg17274064
ERG
1.48 × 10-4
-0.11
cg22809047
RPL31
1.91 × 10-3
-0.10
cg00075967
STRA6
0.010
-0.10
cg06952310
NCAN
7.13 × 10-3
-0.10
cg02388150
SFRP1
3.33 × 10-3
0.10
cg03588357
GPR68
7.72 × 10-3
0.10
cg26297688
TMEM263
6.21 × 10-3
0.10
cg04528819
KLF14
0.036
0.10
cg26372517
TFAP2E
9.23 × 10-3
0.11
cg08030082
POMC
1.93 × 10-3
0.11
cg05675373
KCNC4
7.80 × 10-3
0.11
cg10281002
TBX5
0.012
0.11
cg06117855
CLEC3B
1.87 × 10-3
0.11
cg09509673
CCR10
1.91 × 10-4
0.11
cg14597908
GNAS
1.48 × 10-4
0.11
cg27494383
LTK
9.32 × 10-3
0.12
cg21870884
GPR25
5.77 × 10-3
0.13
cg25657834
NTSR2
4.43 × 10-3
0.13
cg22449114
TCF15
3.48 × 10-5
0.13
cg04126866
C10orf99
4.52 × 10-4
0.13
cg25552492
LGI3
9.44 × 10-3
0.14
cg08965235
LTBP3
3.12 × 10-3
0.14
cg06836772
PRKAA2
0.013
0.14
cg02364642
ARHGEF25
1.20 × 10-3
0.16
cg18573383
KCNC2
1.38 × 10-3
0.16
cg12616277
ESYT3
0.015
0.16
cg17729667
NINL
3.46 × 10-3
0.16
cg04999691
ZBED6CL
3.32 × 10-11
0.16
cg12373771
CECR6
3.70 × 10-3
0.17
cg02489552
CCDC105
8.91 × 10-8
0.17
cg25148589
GRIA2
7.77 × 10-6
0.19
cg21096399
MCAM
5.47 × 10-6
0.19
cg20914508
GAP43
4.24 × 10-4
0.20
cg12768605
LYPD5
1.85 × 10-4
0.21
cg13216057
DKK3
2.10 × 10-4
0.21
cg12351433
LHCGR
4.97 × 10-7
0.22
cg08434234
DGKI
5.16 × 10-5
0.23
cg10920957
JPH3
3.00 × 10-4
0.26
cg27092035
ARL10
3.73 × 10-5
0.27
cg06557358
TMEM132E
3.17 × 10-6
0.27
cg26620959
SYNE1
1.32 × 10-6
0.30
cg07663789
NPR3
8.73 × 10-6
0.31
cg09191327
PRDM12
1.79 × 10-6
0.31
cg25070637
SDC2
1.64 × 10-6
0.34
cg10486998
GALR1
1.81 × 10-8
0.35
cg24834740
PPP1R16B
3.56 × 10-12
0.37
cg27319898
ZNF804B
5.41 × 10-8
0.38
cg08090772
ADHFE1
7.18 × 10-14
0.39
cg02217159
KHDRBS2
6.67 × 10-13
0.43
Table 3 Significant DNA methylation changes of age-related CpG sites in adenoma samples compared to normal tissue.
cgID
Gene symbol
P value
Δβ (AD - N)
cg10345936
SLC36A2
3.49 × 10-10
-0.34
cg00091693
KRT20
2.49 × 10-12
-0.30
cg00075967
STRA6
2.58 × 10-9
-0.26
cg11314684
AKT3
1.03 × 10-9
-0.26
cg06462291
NT5DC3
7.45 × 10-5
-0.25
cg17099569
GLI2
1.25 × 10-10
-0.23
cg00168942
GJD4
2.48 × 10-7
-0.20
cg20828084
CEMIP
1.33 × 10-9
-0.19
cg17274064
ERG
1.82 × 10-10
-0.19
cg07408456
PGLYRP2
2.41 × 10-12
-0.19
cg03019000
TEX264
2.25 × 10-7
-0.19
cg17589341
SLC14A1
1.42 × 10-9
-0.19
cg02580606
KRT33B
9.08 × 10-5
-0.17
cg00436603
CYP2E1
1.37 × 10-8
-0.16
cg19346193
UROS
6.59 × 10-7
-0.15
cg03103192
SPATA18
1.39 × 10-7
-0.15
cg25564800
KPNA1
2.18 × 10-8
-0.14
cg06144905
PIPOX
3.63 × 10-7
-0.14
cg06952310
NCAN
2.72 × 10-4
-0.14
cg13038560
C2orf47
2.13 × 10-5
-0.13
cg22190114
NLRP8
1.67 × 10-4
-0.13
cg13302154
MGP
7.27 × 10-6
-0.13
cg01262913
DSCR9
2.67 × 10-6
-0.13
cg14258236
OR5V1
3.71 × 10-4
-0.12
cg13828047
MPI
1.01 × 10-3
-0.12
cg01459453
SELP
1.65 × 10-4
-0.12
cg14894144
LAMA3
2.29 × 10-4
-0.12
cg07337598
ANXA9
2.02 × 10-5
-0.12
cg03270204
DDR1
7.47 × 10-5
-0.12
cg12946225
HMG20B
1.37 × 10-6
-0.11
cg09646392
TNFSF13B
2.66 × 10-5
-0.10
cg19305227
SLC28A2
0.033
-0.10
cg03578041
LARP6
2.22 × 10-5
-0.10
cg07455279
NDUFA3
0.013
-0.10
cg13899108
PDE4C
5.00 × 10-6
0.10
cg04999691
ZBED6CL
4.92 × 10-5
0.10
cg14597908
GNAS
9.38 × 10-5
0.10
cg21870884
GPR25
9.49 × 10-3
0.11
cg12616277
ESYT3
0.022
0.12
cg12373771
CECR6
3.55 × 10-3
0.12
cg17729667
NINL
4.43 × 10-3
0.13
cg02364642
ARHGEF25
2.33 × 10-3
0.14
cg22449114
TCF15
2.39 × 10-5
0.14
cg03565323
ZNF287
4.52 × 10-3
0.14
cg02388150
SFRP1
1.20 × 10-7
0.15
cg12768605
LO×L2
8.01 × 10-3
0.15
cg25657834
NTSR2
1.46 × 10-4
0.16
cg20914508
GAP43
9.41 × 10-4
0.16
cg10281002
TBX5
1.26 × 10-5
0.17
cg02489552
CCDC105
7.16 × 10-8
0.18
cg05675373
KCNC4
1.82 × 10-6
0.18
cg25148589
GRIA2
6.11 × 10-7
0.18
cg13216057
DKK3
9.64 × 10-4
0.18
cg27092035
ARL10
8.81 × 10-4
0.19
cg12351433
LHCGR
2.20 × 10-6
0.20
cg18573383
KCNC2
5.43 × 10-7
0.21
cg08434234
DGKI
6.60 × 10-5
0.22
cg21096399
MCAM
5.20 × 10-8
0.22
cg10920957
JPH3
1.03 × 10-4
0.25
cg08965235
LTBP3
6.03 × 10-10
0.25
cg27319898
ZNF804B
5.48 × 10-5
0.26
cg26620959
SYNE1
3.89 × 10-6
0.29
cg25070637
SDC2
1.82 × 10-5
0.30
cg07663789
NPR3
6.41 × 10-7
0.31
cg09191327
PRDM12
4.08 × 10-7
0.31
cg06557358
TMEM132E
2.04 × 10-8
0.33
cg10486998
GALR1
2.61 × 10-9
0.36
cg24834740
PPP1R16B
2.23 × 10-9
0.36
cg08090772
ADHFE1
5.19 × 10-11
0.39
cg02217159
KHDRBS2
1.87 × 10-11
0.41
Table 4 Significant DNA methylation alterations of age-related CpG sites in colorectal cancer samples compared to adenoma tissue.
cgID
Gene symbol
P value
Δβ (CRC - AD)
cg08965235
LTBP3
9.09 × 10-4
-0.11
cg00945507
SEC61G
1.64 × 10-5
0.10
cg15974053
HSD17B14
2.27 × 10-3
0.10
cg24262469
TIPARP
5.33 × 10-8
0.10
cg07158339
FXN
1.84 × 10-7
0.10
cg11314684
AKT3
4.52 × 10-4
0.10
cg03578041
LARP6
2.57 × 10-9
0.10
cg17853587
NDST3
5.94 × 10-4
0.10
cg07408456
PGLYRP2
1.51 × 10-7
0.11
cg02580606
KRT33B
1.22 × 10-4
0.11
cg03019000
TEX264
5.39 × 10-5
0.11
cg27319898
ZNF804B
0.023
0.12
cg00436603
CYP2E1
1.97 × 10-6
0.12
cg15804973
MAP3K5
6.27 × 10-12
0.12
cg06117855
CLEC3B
1.73 × 10-7
0.13
cg24126851
DCHS1
3.58 × 10-8
0.13
cg16034652
UNC79
4.23 × 10-11
0.13
cg01262913
DSCR9
1.64 × 10-8
0.13
cg26372517
TFAP2E
9.80 × 10-6
0.13
cg03270204
DDR1
4.24 × 10-7
0.13
cg17589341
SLC14A1
7.35 × 10-10
0.13
cg22679120
SNX8
8.16 × 10-9
0.14
cg20828084
CEMIP
2.00 × 10-8
0.14
cg19305227
SLC28A2
1.11 × 10-6
0.14
cg00168942
GJD4
1.18 × 10-7
0.14
cg13038560
C2orf47
8.96 × 10-8
0.15
cg26614073
SCAP
1.33 × 10-9
0.15
cg19346193
UROS
2.09 × 10-8
0.16
cg00075967
STRA6
4.87 × 10-7
0.16
cg03103192
SPATA18
6.07 × 10-12
0.16
cg10345936
SLC36A2
4.09 × 10-6
0.16
cg17099569
GLI2
9.04 × 10-7
0.16
cg04126866
C10orf99
4.23 × 10-10
0.18
cg00091693
KRT20
1.17 × 10-8
0.19
In silico gene expression analysis
Genes belonging to 353 age-related CpG sites were mapped to 768 Affymerix transcript IDs. In the CRC vs N comparison, 215 “epigenetic clock” genes were found to be significantly differentially expressed (P < 0.05), of which 117 were altered with absolute logFC > 0.5 (70 upregulated such as ERG, MGP, MCAM, CEMIP and 47 downregulated like SFRP1, KRT20, CLEC3B, SYNE1) (Supplementary Table 2A). Expression of 196 “epigenetic clock” genes changed significantly (P < 0.05) in adenoma samples compared to healthy normal controls, 102 with absolute logFC higher than 0.5 (47 overexpressed such as CEMIP, PLK1, CCNF and 55 underexpressed like SFRP1, SDC2, SYNE1) (Supplementary Table 2B). Forty-three genes including MCAM, MGP and AKT3 showed increased expression in CRC compared to adenoma samples, while 17 genes including CEMIP, SPATA18 were downregulated (P < 0.05, absolute logFC > 0.5) (Supplementary Table 2C).
For genes with an inverse relation between gene expression and promoter methylation, the genes with both significant mRNA expression changes with absolute logFC > 0.5 and significant DNA methylation alterations with at least 10% difference were taken into consideration. Based on these criteria, eleven genes, including ERG, MGP, PIPOX, CLEC3B, LTK, SFRP1 and SYNE1 were found to be inversely expressed with the promoter methylation status in CRC compared to normal tissue. Compared to the promoter methylation alterations, the expression of 8 genes, including CEMIP, SPATA18, SDC2, SFRP1 and SYNE1 changed oppositely in AD vs N comparison, while in CRC vs AD tissues 3 genes, namely CEMIP, SPATA18 and SLC28A2 showed this expression pattern. The genes showing an inverse relation between gene expression and DNA methylation in CRC vs normal, AD vs normal and CRC vs AD comparisons are represented in Table 5.
Table 5 Genes showing inverse DNA methylation and gene expression data.
Protein kinase AMP-activated catalytic subunit alpha 2
cg06836772
0.013
0.14
227892_at
4.15 × 10-3
-0.87
238489_at
4.67 × 10-3
-0.22
SFRP1
Secreted frizzled related protein 1
cg02388150
3.33 × 10-3
0.10
202036_s_at
8.66 × 10-8
-1.47
202037_s_at
3.98 × 10-5
-1.11
202035_s_at
0.039
-0.28
SYNE1
Spectrin repeat containing nuclear envelope protein 1
cg26620959
1.32 × 10-6
0.30
209447_at
4.27 × 10-5
-0.63
AD vs N
CEMIP
Cell migration inducing hyaluronan binding protein
cg20828084
1.33 × 10-9
-0.17
1554685_a_at
1.71 × 10-11
1.12
212942_s_at
2.41 × 10-43
6.88
NT5DC3
5'-nucleotidase domain containing 3
cg06462291
7.45 × 10-5
-0.25
218786_at
6.83 × 10-9
0.76
SPATA18
Spermatogenesis associated 18
cg03103192
1.39 × 10-7
-0.15
230723_at
4.41 × 10-5
0.45
229331_at
1.20 × 10-10
1.50
DKK3
Dickkopf WNT signaling pathway inhibitor 3
cg13216057
9.64 × 10-4
0.18
202196_s_at
9.82 × 10-5
-0.65
214247_s_at
1.52 × 10-4
-0.50
PPP1R16B
Protein phosphatase 1 regulatory subunit 16B
cg24834740
2.23 × 10-9
0.36
41577_at
1.20 × 10-10
-1.44
212750_at
3.28 × 10-7
-0.81
SDC2
Syndecan 2
cg25070637
1.82 × 10-5
0.30
212158_at
1.74 × 10-10
-1.17
212157_at
2.14 × 10-8
-0.66
212154_at
9.19 × 10-5
-0.64
SFRP1
Secreted frizzled related protein 1
cg02388150
1.20 × 10-7
0.15
202036_s_at
3.62 × 10-13
-1.79
202037_s_at
4.43 × 10-11
-1.48
202035_s_at
0.016
-0.32
SYNE1
Spectrin repeat containing nuclear envelope protein 1
cg26620959
3.89 × 10-6
0.29
209447_at
5.76 × 10-15
-1.19
CRC vs AD
CEMIP
Cell migration inducing hyaluronan binding protein
cg20828084
2.00 × 10-8
0.14
212942_s_at
9.88 × 10-3
-1.17
SLC28A2
Solute carrier family 28 member 2
cg19305227
1.11 × 10-6
0.14
207249_s_at
0.027
-1.24
SPATA18
Spermatogenesis associated 18
cg03103192
6.07 × 10-12
0.16
229331_at
3.52 × 10-9
-1.73
230723_at
7.35 × 10-4
-0.41
In the comparison of healthy young colonic samples and normal adult tissues, 150 genes showed significantly altered expression from which 94 genes with absolute logFC > 0.5 including overexpressed LTBP3, REEP1, MGP, PLK1, SFRP1, SYNE1 and downregulated PRKG2, PDCD6IP and TMEM56 (P < 0.05) (Supplementary Table 2D). The pattern of expression of several genes including SYNE1, CLEC3B, LTBP3 (Figure 2) and SFRP1 (Figure 3A-C) was similar for increased age as that observed for cancer progression. However, there were some genes such as MGP (Figure 2) which showed similar expression pattern in young people and in cancer patients compared to healthy adult tissue.
Figure 2 Genes showing both age- and carcinogenesis-related expression alterations.SYNE1 (spectrin repeat containing nuclear envelope protein 1), LTBP3 (latent transforming growth factor beta binding protein 3) and CLEC3B (C-type lectin domain family 3 member B) genes were downregulated during the colorectal carcinogenesis, similar decreasing expression was found during aging (significantly higher mRNA levels were detected in young colonic samples than in healthy adult biopsy specimens). MGP (matrix Gla protein) was overexpressed in children and in CRC samples compared to adenoma and healthy adults (P < 0.035), hence its opposite expression was found during aging and colorectal carcinogenesis. X axis shows the analyzed sample groups, the normalized mRNA expression can be seen on Y axis. Red dots indicate the normalized mRNA expression values, boxplots represent the medians and standard deviations. Ch: Children; N: Normal; Ad: Adenoma; CRC: Colorectal cancer.
Figure 3 SFRP1 mRNA expression and promoter DNA methylation alterations during aging and in different stages of colorectal carcinogenesis.SFRP1 mRNA expression was significantly downregulated in adenoma and CRC samples compared to normal controls in case of all three Affymetrix probeset IDs representing SFRP1 [202035_s_at: P < 0.05 (A); 202036_s_at: P < 0.0003 (B); 202037_s_at: P < 0.005 (C)]. In colonic biopsy samples of healthy young patients, higher SFRP1 mRNA levels could be measured than in normal adults samples, this overexpression was proven to be significant in two of three transcript IDs [202035_s_at: P < 0.05 (A); 202037_s_at: P < 0.005 (C)]. SFRP1 promoter region was significantly hypermethylated in CRC and adenoma tissue samples compared to normal adult and young colonic tissue (P < 0.0001) (D). In pairwise comparison, DNA methylation of SFRP1 promoter was slightly, but significantly increased in healthy adults compared to normal young samples (P < 0.02) (E). The analyzed sample groups are illustrated on X axis, the normalized mRNA expression (A, B, C) and percentage of SFRP1 promoter methylation (D, E) are represented on Y axis. Red dots indicate the normalized mRNA expression values (A, B, C) and the normalized DNA methylation percentage values (D, E), respectively. Boxplots represent the medians and standard deviations. Ch: Children; N: Normal; Ad: Adenoma; CRC: Colorectal cancer.
Whole promoter methylation status of genes showing inverse relationship between gene expression and DNA methylation
The DNA methylation status of whole promoter regions of genes showing an inverse relation between gene expression and DNA methylation (Table 5) was determined using methyl capture sequencing data of 6 NAT, 15 adenoma and 9 CRC tissue samples[12]. In the CRC vs N/NAT comparison, similar DNA methylation alterations (such as hypomethylated AKT3, MGP promoters and hypermethylated PPP1R16B, SFRP1, SYNE1 promoters) were observed in the promoter regions of 7 of the 11 inversely expressed genes (Table 6). Between adenoma and normal samples, promoter regions of 7 of the 8 inversely expressed genes showed DNA methylation differences (e.g., hypomethylated CEMIP/KIAA1199, SPATA18 promoters and hypermethylated DKK3, SDC2, SFRP1, SYNE1 promoters) (Table 6) as detected in case of age-related CpG sites. In CRC samples compared to adenoma tissue, significant hypermethylation of CEMIP/KIAA199 promoter could be demonstrated in “epigenetic clock” CpG sites and whole promoter methylation analyses (Table 6).
Table 6 Whole promoter methylation status of genes with inverse age-related CpG site DNA methylation and gene expression data.
Gene symbol
DNA methylation on age-related CpG site
Whole promoter DNA methylation status
cg ID
P value
Δβ
Start-Stop position
P value
Δβ
CRC vs N
AKT3
cg11314684
4.55 × 10-5
-0.16
chr1:244005801-244005900
6.56 × 10-3
-0.33
ERG
cg17274064
1.48 × 10-4
-0.11
chr21:39871501-39871600
0.044
-0.21
MGP
cg00431549
0.020
-0.12
chr12:15038501-15038600
0.030
-0.27
CCR10
cg09509673
1.91 × 10-4
0.11
chr17:40835101-40835200
0.045
0.18
chr17:40835201-40835300
0.022
0.26
PPP1R16B
cg24834740
3.56 × 10-12
0.37
chr20:37433201-37433300
3.76 × 10-3
0.35
chr20:37434701-37434800
0.048
0.40
chr20:37435301-37435400
0.042
0.37
SFRP1
cg02388150
3.33 × 10-3
0.10
chr8:41166001-41166100
0.017
0.44
chr8:41166101-41166200
1.31 × 10-4
0.56
chr8:41166201-41166300
3.40 × 10-3
0.49
chr8:41166301-41166400
0.014
0.27
chr8:41166401-41166500
1.28 × 10-3
0.53
chr8:41166501-41166600
0.027
0.44
chr8:41166601-41166700
0.034
0.39
chr8:41166901-41167000
0.042
0.41
SYNE1
cg26620959
1.32 × 10-6
0.30
chr6:152622201-152622300
0.027
0.35
chr6:152957601-152957700
0.032
0.39
chr6:152957701-152957800
0.043
0.40
chr6:152958101-152958200
2.86 × 10-4
0.65
AD vs N
CEMIP
cg20828084
1.33 × 10-9
-0.17
chr15: 81070701-81070800
0.028
-0.25
SPATA18
cg03103192
1.39 × 10-7
-0.15
chr4:52915901-52916000
0.042
-0.23
DKK3
cg13216057
9.64 × 10-4
0.18
chr11:12029701-12029800
3.11 × 10-3
0.26
chr11:12029801-12029900
1.67 × 10-3
0.33
chr11:12029901-12030000
8.08 × 10-5
0.56
chr11:12030001-12030100
0.047
0.15
chr11:12030401-12030500
7.38 × 10-3
0.28
chr11: 12030501-12030600
0.012
0.28
PPP1R16B
cg24834740
2.23 × 10-9
0.36
chr20:37434201-37434300
0.045
0.26
chr20:37434601-37434700
0.022
0.39
chr20:37434701-37434800
0.013
0.39
chr20:37434801-37434900
6.87 × 10-3
0.30
chr20:37434901-37435000
1.70 × 10-3
0.44
chr20:37435001-37435100
1.93 × 10-3
0.45
chr20:37435101-37435200
6.49 × 10-3
0.35
chr20:37435201-37435300
8.93 × 10-4
0.51
chr20:37435301-37435400
0.014
0.42
SDC2
cg25070637
1.82 × 10-5
0.30
chr8:97505901-97506000
2.30 × 10-3
0.59
chr8:97506101-97506200
1.96 × 10-4
0.65
chr8:97506201-97506300
8.43 × 10-4
0.63
chr8:97506301-97506400
0.012
0.49
chr8:97506401-97506500
0.019
0.47
chr8:97506601-97506700
3.99 × 10-3
0.51
chr8:97506701-97506800
0.021
0.45
chr8:97506801-97506900
0.014
0.52
chr8:97507101-97507200
0.015
0.44
chr8:97507201-97507300
0.010
0.52
chr8:97507301-97507400
3.47 × 10-3
0.59
SFRP1
cg02388150
1.20 × 10-7
0.15
chr8:41165901-41166000
2.30 × 10-3
0.59
chr8:41166001-41166100
1.57 × 10-3
0.59
chr8:41166101-41166200
3.54 × 10-4
0.56
chr8:41166201-41166300
1.49 × 10-4
0.60
chr8:41166301-41166400
6.54 × 10-3
0.27
chr8:41166401-41166500
1.32 × 10-5
0.55
chr8: 41166501-41166600
2.30 × 10-3
0.60
chr8:41166601-41166700
5.45 × 10-3
0.57
chr8:41166701-41166800
8.15 × 10-3
0.51
chr8:41166801-41166900
0.032
0.39
chr8:41166901-41167000
0.019
0.45
chr8:41167001-41167100
0.046
0.34
chr8:41167101-41167200
0.025
0.41
chr8:41167201-41167300
0.024
0.40
SYNE1
cg26620959
3.89 × 10-6
0.29
chr6:152702701-152702800
0.012
0.20
chr6:152702801-152702900
0.035
0.21
chr6:152957501-152957600
6.05 × 10-4
0.37
chr6:152957601-152957700
2.34 × 10-4
0.60
chr6:152957701-152957800
0.017
0.51
chr6:152957801-152957900
1.09 × 10-3
0.42
chr6:152957901-152958000
1.03 × 10-4
0.57
chr6:152958001-152958100
7.13 × 10-4
0.43
chr6:152958101-152958200
1.72 × 10-5
0.72
CRC vs AD
CEMIP
cg20828084
2.00 × 10-8
0.14
chr15:81070701-81070800
7.59 × 10-4
0.31
chr15:81070801-81070900
0.011
0.36
SFRP1 promoter methylation analysis in healthy children, healthy adult, adenoma and CRC tissues
Based on the gene expression analysis results, SFRP1 was found to be overexpressed in normal adult samples compared to adenoma and CRC biopsy specimens, and in healthy young patients even higher SFRP1 mRNA levels could be detected than in normal adult samples (Figure 3A-C). As SFRP1 is proven to be a methylation-regulated gene with literature data regarding its age-related DNA methylation alterations, hence it was chosen for detailed methylation analysis of normal, premalignant and cancerous colonic specimens including tissue samples from healthy children.
SFRP1 promoter sequences were highly methylated in CRC samples (average methylation% = 55.0% ± 8.4%) and in adenoma tissue (49.9% ± 18.1 %), while low methylation levels could be measured in colonic tissues of both healthy adults (5.2% ± 2.7%) and children (2.2% ± 0.7%). Significant considerable hypermethylation was found in SFRP1 promoter both between CRC and adult normal and between CRC and healthy children colonic tissue samples (P < 0.0001) (Figure 3D). In the healthy adult vs healthy children comparison, significant, but moderate DNA methylation alterations were detected: in adults higher DNA methylation levels were found in the analyzed region of SFRP1 promoter (P = 0.017) (Figure 3E).
SFRP1 protein expression in colonic tissue samples of healthy normal children and adults
In healthy children samples the epithelial layer showed strong (representative scoring values: +3 and +2), diffuse SFRP1 expression both in cytoplasmic and nuclear region (Q-score: 226.67 ± 17.51), whereas the stromal cells showed heterogeneous protein expression (scoring values: form +3 to 0; Q-score: 176.66 ± 18.61; ΣQ-score: 403.33 ± 22.51; Figure 4A). Among stromal cells subepithelial fibroblast and several immune cells showed strong cytoplasmic and/or nuclear SFRP1 expression. Not significantly, but remarkably lower (representative scoring value: +2) SFRP1 protein expression was detectable both in epithelial (Q-score: 202.14 ± 24.12) and stromal component (140.71 ± 41.47; Σ Q-score: 351.42 ± 68.66; Figure 4B) of adult persons (P values: 0.063, 0.073 and 0.105 respectively).
Figure 4 SFRP1 protein expression in colonic tissue samples of healthy normal children and adults.
Strong/moderate cytoplasmic and nuclear SFRP1 expression both in epithelial and stromal compartments of healthy children (A) and healthy adult (B) samples. Digital microscopic images; magnification × 40; scale: 50 μm.
DISCUSSION
Cancer is considered a primary age-related disease[3], and therefore age-related molecular changes including epigenetic alterations such as epigenetic drift and epigenetic clock[1,2] necessarily show relationship with carcinogenesis-associated differences. Besides global hypomethylation, local, genomic site specific hypermethylation principally in the promoter regions of tumor suppressor genes can occur during both processes[6-8].
In this study, the potential correspondence between age-related and CRC-associated DNA methylation changes was studied using the 353 epigenetic clock CpG sites published by Horvath[2] as a model for age-related DNA methylation changes. With the analysis of methyl capture sequencing and Illumina BeadChip450K methylation array data, the methylation status of age-related CpG sites and genes was determined during CRC development and progression, and the relevant mRNA expression changes were also evaluated. Among the differentially methylated/expressed age-related genes, SFRP1 promoter methylation was further analyzed in healthy, premalignant and cancerous colonic tissue samples, including biopsy specimens from young children.
Similarly to previous findings[29], DNA methylation alterations in a considerable proportion of age-related CpG sites/gene promoters (approximately 40%) were observed in samples representing different stages of CRC formation and progression. Approximately two third of these CpG sites had similar DNA methylation alterations in CRC compared to normal tissue samples as during aging. When the effect of DNA methylation of epigenetic clock genes was studied, whole promoter methylation was also observed in addition to the analysis of DNA methylation status of representing age-related CpG sites.
In accordance with our results, hypermethylation of several genes belonging to aging-associated CpG sites such as SFRP1[7,12,15,18-23], TFAP2E[30], TBX5[31], GNAS[32], DKK3[18,33], DGKI[34], SYNE1[35-37], SDC2[38,39], ADHFE1[40-42] was observed in tissue and/or blood samples of CRC patients. SFRP1 tumor suppressor protein with a putative Wnt-binding site impedes the frizzled ligand - Wnt receptor interaction. Its reduced expression caused by promoter hypermethylation can lead to constitutive activation of Wnt pathway which is best characterized signaling pathway in CRC pathogenesis[7,12,15,18-23,43]. Worthley et al[15] showed strong positive correlation between SFRP1 methylation and age (Spearmen’s rank P = 0.72, P < 0.0001) on a set of 166 CRC tissue samples from adults [median age: 61.2 years (22.8-89.2 years)]. In this study, the increase of SFRP1 methylation during the aging was also observed, moreover to our best knowledge, we provide the first evidence of significantly lower SFRP1 methylation levels in children (under 18 years) compared to healthy adult colonic tissues. Preliminary results of methylation-sensitive restriction enzyme methylation array analysis of our reseach groups suggested SFRP1 hypomethylation in young colonic tissue samples, though the high standard deviations of methylation percentages and the low samples size limited our conclusions[18]. In accordance with the DNA methylation data, elevated mRNA and protein levels could be detected in colonic tissues of normal children compared to adults.
Dickkopf Wnt signaling pathway inhibitors including DKK3 are also frequent targets of epigenetic silencing in gastrointestinal tumors promoting carcinogenesis by loss of/reduction their expression[33]. Hypermethylated syndecan 2 (SDC2) is a potential biomarker for early CRC detection both in serum and tissue, although the gene silencing effect of elevated promoter methylation is not unambiguous according to the literature data[44], moreover some observations support its tumorigenic activity in CRC[45]. Hypermethylation of spectrin repeat containing nuclear envelope protein 1 (SYNE1) suggests its tumor suppressor function in CRC[37], which was detected not only in CRC tissue samples[35,36], but it appears to be a promising marker for blood-based CRC detection[37]. Alcohol dehydrogenase, iron containing 1 (ADHFE1) promoter hypermethylation was found to be associated with CRC differentiation[41], furthermore it is involved in cell proliferation induction by alcohol in colon carcinoma cells[46].
In the case of some genes like AKT3, CEMIP and DDR1, promoter hypomethylation was observed in different types of cancers such as breast cancer, lung cancer and CRC[47-49]. PI3K/Akt pathway is thought to be the most commonly activated intracellular signaling pathway in human malignancies[50]. AKT kinases including AKT3 are remarkable contributors to malignant diseases as they are involved in the regulation of cell proliferation, growth and survival[50,51]. Hypomethylation and overexpression of the cell migration-inducing protein (CEMIP/KIAA1199) was previously described in CRC[49,52]. In our study, hypomethylation of this gene could be detected mainly in adenoma samples, however a slight but significant decrease in methylation level was observed in CRC samples compared to normal controls. In accordance with the methylation data, strong upregulation of CEMIP mRNAs was shown both in adenoma and CRC samples with higher expression values in adenoma tissue[53,54]. Due to its robust overexpression at mRNA and also at protein levels, CEMIP is considered as a candidate prognostic marker for CRC and a potential therapeutic target[55]. CEMIP facilitates colon cancer cell proliferation via enhancing Wnt signaling[49] and promotes tumor growth[55] and cancer dissemination under hypoxic conditions[56].
In conclusion, our results regarding DNA methylation alterations of age-related, epigenetic clock genes during colorectal carcinogenesis supports the concept that aging is one of the main factors predisposing cancer including CRC. Several age-related DNA methylation alterations could be observed during development and progression of CRC affecting the mRNA expression of certain CRC- and adenoma-related key control genes. The main CRC-associated signal transduction pathways, such as WNT signaling and PI3K/Akt pathways are also influenced during aging.
ACKNOWLEDGMENTS
We thank hereby the help of Gabriella Kónyáné Farkas with the immunohistochemical analysis. Furthermore we thank Theo deVos PhD for his careful language assistance.
COMMENTS
Background
Cancer is considered a primary age-related disease, and therefore age-related molecular changes including epigenetic alterations such as epigenetic drift and epigenetic clock necessarily show relationship with carcinogenesis-associated differences. Besides global hypomethylation, local, genomic site specific hypermethylation principally in the promoter regions of tumor suppressor genes can occur during both processes.
Research frontiers
Several age-related DNA methylation alterations could be observed during colorectal cancer (CRC) formation and progression affecting the mRNA expression of certain CRC- and adenoma-related key control genes such as hypermethylated secreted frizzled related protein 1 (SFRP1), spectrin repeat containing nuclear envelope protein 1 and hypomethylated cell migration-inducing protein.
Innovations and breakthroughs
For the first time significantly lower SFRP1 methylation levels were demonstrated in colonic tissue from children (under 18 years) compared to healthy adults. The main CRC-associated signal transduction pathways, such as WNT signaling and PI3K/Akt pathways are also influenced during aging.
Peer-review
In this paper, the authors analyzed the methylation and expression levels of 353 age-related “epigenetic clock” genes in colonic tissue samples. They identified many differentially methylated and/or differentially expressed genes. Among these genes, the DNA methylation and mRNA levels of SFRP1 was further analyzed. This is an interesting work using a large number of data and the results may be useful in related field.
Footnotes
Manuscript source: Invited manuscript
Specialty type: Gastroenterology and hepatology
Country of origin: Hungary
Peer-review report classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C, C, C, C
Grade D (Fair): 0
Grade E (Poor): 0
P- Reviewer: Essani K, Lakatos PL, M’Koma A, Xiao Y, Lakatos PL S- Editor: Yu J L- Editor: A E- Editor: Wang CH
Galamb O, Kalmár A, Péterfia B, Csabai I, Bodor A, Ribli D, Krenács T, Patai ÁV, Wichmann B, Barták BK, Tóth K, Valcz G, Spisák S, Tulassay Z, Molnár B. Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer.Epigenetics. 2016;11:588-602.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 48][Cited by in F6Publishing: 55][Article Influence: 6.9][Reference Citation Analysis (0)]
Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt KA, Le Leu RK, Winter J, Hu Y. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer.Oncogene. 2010;29:1653-1662.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 82][Cited by in F6Publishing: 91][Article Influence: 6.1][Reference Citation Analysis (0)]
Patai ÁV, Valcz G, Hollósi P, Kalmár A, Péterfia B, Patai Á, Wichmann B, Spisák S, Barták BK, Leiszter K, Tóth K, Sipos F, Kovalszky I, Péter Z, Miheller P, Tulassay Z, Molnár B. Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas.PLoS One. 2015;10:e0133836.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 36][Cited by in F6Publishing: 39][Article Influence: 4.3][Reference Citation Analysis (0)]
Kalmár A, Péterfia B, Hollósi P, Wichmann B, Bodor A, Patai ÁV, Schöller A, Krenács T, Tulassay Z, Molnár B. Bisulfite-Based DNA Methylation Analysis from Recent and Archived Formalin-Fixed, Paraffin Embedded Colorectal Tissue Samples.Pathol Oncol Res. 2015;21:1149-1156.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 9][Cited by in F6Publishing: 9][Article Influence: 1.0][Reference Citation Analysis (0)]
Kalmár A, Péterfia B, Hollósi P, Galamb O, Spisák S, Wichmann B, Bodor A, Tóth K, Patai ÁV, Valcz G, Nagy ZB, Kubák V, Tulassay Z, Kovalszky I, Molnár B. DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer.BMC Cancer. 2015;15:736.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 35][Cited by in F6Publishing: 45][Article Influence: 5.0][Reference Citation Analysis (0)]
Silva AL, Dawson SN, Arends MJ, Guttula K, Hall N, Cameron EA, Huang TH, Brenton JD, Tavaré S, Bienz M. Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists.BMC Cancer. 2014;14:891.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 52][Cited by in F6Publishing: 63][Article Influence: 6.3][Reference Citation Analysis (0)]
Galamb O, Györffy B, Sipos F, Spisák S, Németh AM, Miheller P, Tulassay Z, Dinya E, Molnár B. Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature.Dis Markers. 2008;25:1-16.
[PubMed] [DOI][Cited in This Article: ]
Leiszter K, Galamb O, Sipos F, Krenács T, Veres G, Wichmann B, Kalmár A, Patai ÁV, Tóth K, Valcz G, Molnár B, Tulassay Z. Sporadic colorectal cancer development shows rejuvenescence regarding epithelial proliferation and apoptosis.PLoS One. 2013;8:e74140.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 10][Cited by in F6Publishing: 10][Article Influence: 0.9][Reference Citation Analysis (0)]
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer.Proc Natl Acad Sci USA. 1999;96:8681-8686.
[PubMed] [DOI][Cited in This Article: ]
Beggs AD, Dilworth MP, Domingo E, Midgley R, Kerr D, Tomlinson IP, Middleton GW. Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & amp; disease free survival in colorectal cancer.Oncoscience. 2015;2:508-516.
[PubMed] [DOI][Cited in This Article: ]
Naumov VA, Generozov EV, Zaharjevskaya NB, Matushkina DS, Larin AK, Chernyshov SV, Alekseev MV, Shelygin YA, Govorun VM. Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips.Epigenetics. 2013;8:921-934.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 93][Cited by in F6Publishing: 106][Article Influence: 9.6][Reference Citation Analysis (0)]
Nelson HH, Marsit CJ, Christensen BC, Houseman EA, Kontic M, Wiemels JL, Karagas MR, Wrensch MR, Zheng S, Wiencke JK. Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling.Epigenetics. 2012;7:559-566.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 35][Cited by in F6Publishing: 36][Article Influence: 3.0][Reference Citation Analysis (0)]
Tiwari A, Schneider M, Fiorino A, Haider R, Okoniewski MJ, Roschitzki B, Uzozie A, Menigatti M, Jiricny J, Marra G. Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors.PLoS One. 2013;8:e69473.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 42][Cited by in F6Publishing: 50][Article Influence: 4.5][Reference Citation Analysis (0)]